Target Name: RTKN2
NCBI ID: G219790
Other Name(s): OTTHUMP00000035699 | Pleckstrin homology domain-containing family K member 1 | RTKN2_HUMAN | bA531F24.1 | Rhotekin-2 (isoform 1) | PLEKHK1 | RTKN2 variant 1 | rhotekin 2 | Rhotekin-2 | Pleckstrin homology domain containing, family K member 1 | PH domain-containing family K member 1 | Rhotekin 2, transcript variant 1 | BA531F24.1 | DKFZp686J10120 | pleckstrin homology domain-containing family K member 1

RTKN2: A Potential Drug Target and Biomarker

RTKN2, short for Retinal-Tubulin Kinesin 2, is a protein that is expressed in the retina and is involved in the movement of photoreceptors in the retina to the photoreceptor neurons. It is a key component of the phototransduction pathway, which is the process by which light is converted into electrical signals that are sent to the brain.

Recent studies have identified RTKN2 as a potential drug target and biomarker for a variety of diseases, including neurodegenerative disorders, uveal cancer, and diabetic retinopathy.

One of the reasons for the potential drug targeting of RTKN2 is its unique structure and biology. Unlike most proteins, RTKN2 is a member of the kinesin family, which is known for their ability to transport molecules along the length of their protein fibers. This property makes RTKN2 a unique candidate for drug targeting because it can be targeted directly with small molecules.

In addition, RTKN2's expression is highly tissue-specific, which means that it is expressed in high levels in the retina but is not found in other tissues. This can make it an attractive target for drugs that are designed to localize to specific tissues and organs.

Another potential drug target for RTKN2 is its role in the development and progression of several diseases. For example, studies have shown that high levels of RTKN2 are associated with the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Additionally, high levels of RTKN2 have been detected in the retina of individuals with uveal cancer, which is a type of eye cancer that can be particularly aggressive.

In addition to its potential drug targeting properties, RTKN2 has also been identified as a potential biomarker for several diseases. For example, studies have shown that levels of RTKN2 are elevated in the retina of individuals with neurodegenerative disorders, which suggests that it may be a useful biomarker for these conditions. Additionally, high levels of RTKN2 have been detected in the retina of individuals with uveal cancer, which could be used as a biomarker for this disease.

In conclusion, RTKN2 is a protein that is expressed in the retina and is involved in the movement of photoreceptors in the retina. Its unique structure and biology, as well as its potential drug targeting properties, make it an attractive candidate for drug development for a variety of diseases. Additionally, its potential as a biomarker for neurodegenerative disorders and uveal cancer makes it an important target for further research in these fields.

Protein Name: Rhotekin 2

Functions: May play an important role in lymphopoiesis

More Common Targets

RTL1 | RTL10 | RTL3 | RTL4 | RTL5 | RTL6 | RTL8A | RTL8B | RTL8C | RTL9 | RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4